167 related articles for article (PubMed ID: 20083418)
1. CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.
McGovern DL; Mosier PD; Roth BL; Westkaemper RB
J Mol Graph Model; 2010 Apr; 28(7):612-25. PubMed ID: 20083418
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
3. Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.
Polepally PR; Huben K; Vardy E; Setola V; Mosier PD; Roth BL; Zjawiony JK
Eur J Med Chem; 2014 Oct; 85():818-29. PubMed ID: 25193297
[TBL] [Abstract][Full Text] [Related]
4. A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.
Singh N; Chevé G; Ferguson DM; McCurdy CR
J Comput Aided Mol Des; 2006; 20(7-8):471-93. PubMed ID: 17009091
[TBL] [Abstract][Full Text] [Related]
5. Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.
Lozama A; Cunningham CW; Caspers MJ; Douglas JT; Dersch CM; Rothman RB; Prisinzano TE
J Nat Prod; 2011 Apr; 74(4):718-26. PubMed ID: 21338114
[TBL] [Abstract][Full Text] [Related]
6. O6C-20-nor-salvinorin A is a stable and potent KOR agonist.
Hirasawa S; Cho M; Brust TF; Roach JJ; Bohn LM; Shenvi RA
Bioorg Med Chem Lett; 2018 Sep; 28(16):2770-2772. PubMed ID: 29426768
[TBL] [Abstract][Full Text] [Related]
7. A review of salvinorin analogs and their kappa-opioid receptor activity.
Roach JJ; Shenvi RA
Bioorg Med Chem Lett; 2018 May; 28(9):1436-1445. PubMed ID: 29615341
[TBL] [Abstract][Full Text] [Related]
8. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.
Vortherms TA; Mosier PD; Westkaemper RB; Roth BL
J Biol Chem; 2007 Feb; 282(5):3146-56. PubMed ID: 17121830
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
Ansonoff MA; Zhang J; Czyzyk T; Rothman RB; Stewart J; Xu H; Zjwiony J; Siebert DJ; Yang F; Roth BL; Pintar JE
J Pharmacol Exp Ther; 2006 Aug; 318(2):641-8. PubMed ID: 16672569
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.
Yan F; Bikbulatov RV; Mocanu V; Dicheva N; Parker CE; Wetsel WC; Mosier PD; Westkaemper RB; Allen JA; Zjawiony JK; Roth BL
Biochemistry; 2009 Jul; 48(29):6898-908. PubMed ID: 19555087
[TBL] [Abstract][Full Text] [Related]
11. Salvinorin A: allosteric interactions at the mu-opioid receptor.
Rothman RB; Murphy DL; Xu H; Godin JA; Dersch CM; Partilla JS; Tidgewell K; Schmidt M; Prisinzano TE
J Pharmacol Exp Ther; 2007 Feb; 320(2):801-10. PubMed ID: 17060492
[TBL] [Abstract][Full Text] [Related]
12. A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist.
Kane BE; Nieto MJ; McCurdy CR; Ferguson DM
FEBS J; 2006 May; 273(9):1966-74. PubMed ID: 16640560
[TBL] [Abstract][Full Text] [Related]
13. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL
J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611
[TBL] [Abstract][Full Text] [Related]
14. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
Butelman ER; Mandau M; Tidgewell K; Prisinzano TE; Yuferov V; Kreek MJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):300-6. PubMed ID: 17060493
[TBL] [Abstract][Full Text] [Related]
15. A structure-affinity and comparative molecular field analysis of sigma-2 (sigma2) receptor ligands.
Abate C; Mosier PD; Berardi F; Glennon RA
Cent Nerv Syst Agents Med Chem; 2009 Sep; 9(3):246-57. PubMed ID: 20021358
[TBL] [Abstract][Full Text] [Related]
16. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
Butelman ER; Rus S; Prisinzano TE; Kreek MJ
Psychopharmacology (Berl); 2010 Jun; 210(2):253-62. PubMed ID: 20084367
[TBL] [Abstract][Full Text] [Related]
17. Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.
Béguin C; Duncan KK; Munro TA; Ho DM; Xu W; Liu-Chen LY; Carlezon WA; Cohen BM
Bioorg Med Chem; 2009 Feb; 17(3):1370-80. PubMed ID: 19147366
[TBL] [Abstract][Full Text] [Related]
18. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
Peng Y; Keenan SM; Zhang Q; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):25-33. PubMed ID: 15950508
[TBL] [Abstract][Full Text] [Related]
20. Semisynthetic neoclerodanes as kappa opioid receptor probes.
Lovell KM; Vasiljevik T; Araya JJ; Lozama A; Prevatt-Smith KM; Day VW; Dersch CM; Rothman RB; Butelman ER; Kreek MJ; Prisinzano TE
Bioorg Med Chem; 2012 May; 20(9):3100-10. PubMed ID: 22464684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
